title: 90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10(6) cells/L.
abstract: OBJECTIVE
  To evaluate the ability of serum levels of 90K, previously reported as a progression marker of human immunodeficiency virus infection, to predict the future rate of CD4 lymphocyte decline.
  
  
  METHODS
  Retrospective analysis of data from outpatients enrolled in a multi-institutional study.
  
  
  METHODS
  One hundred five human immunodeficiency virus-positive intravenous drug users who had at least six serial CD4 lymphocyte measurements and starting CD4 levels of 200 x 10(6) cells/L or higher.
  
  
  METHODS
  Rate of CD4 lymphocyte decline.
  
  
  RESULTS
  During a median follow-up of 28 months (range, 20-36 months), the estimated loss of CD4 cells in the whole patient population was 3.4 x 106 cells/L per month (P = .0045). Subjects who were on zidovudine treatment at study entry showed an average loss of 3.8 x 10(6) cells/L per month, significantly higher than in untreated subjects (P = .02), but similar to the loss observed for those requiring initiation of treatment during the course of the study. At baseline, 56 subjects had 90K levels of 10 microg/mL or less, and 49 had more than 10 microg/mL. The rate of CD4 decline in the high-90K group was approximately 5 x 10(6) cells/L per month (P < .0015), whereas in the low-90K group it was not different from zero (P = ns). No difference emerged in the rate of CD4 decline when subjects were stratified according to baseline 90K levels and zidovudine treatment, beta2-microglobulin, or neopterin serum levels.
  
  
  CONCLUSIONS
  90K serum levels are predictive of CD4 decline.
authors.affiliation: Department of Medical Oncology, University G. D'Annunzio Medical School, Chieti, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Tinari
authors.forename: C
authors.initials: C
authors.lastname: Natoli
authors.forename: N
authors.initials: N
authors.lastname: D'Ostilio
authors.forename: F
authors.initials: F
authors.lastname: Ghinelli
authors.forename: L
authors.initials: L
authors.lastname: Sighinolfi
authors.forename: L
authors.initials: L
authors.lastname: Ortona
authors.forename: E
authors.initials: E
authors.lastname: Tamburrini
authors.forename: M
authors.initials: M
authors.lastname: Piazza
authors.forename: A
authors.initials: A
authors.lastname: Chirianni
authors.forename: L
authors.initials: L
authors.lastname: Guerra
authors.forename: P
authors.initials: P
authors.lastname: Di Gregorio
authors.forename: S
authors.initials: S
authors.lastname: Iacobelli
mesh_terms: D000951:Antigens, Neoplasm; D015415:Biomarkers / Q000097:blood; D014408:Biomarkers, Tumor; D018791:CD4 Lymphocyte Count; D002352:Carrier Proteins / Q000097:blood*; D006023:Glycoproteins / Q000097:blood*; D015658:HIV Infections / Q000097:blood / Q000175:diagnosis / Q000276:immunology*; D006801:Humans; D011379:Prognosis; D012189:Retrospective Studies; D016326:Extracellular Matrix Proteins
chemical_list: D000951:Antigens, Neoplasm; D015415:Biomarkers; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D006023:Glycoproteins; C081856:LGALS3BP protein, human; D016326:Extracellular Matrix Proteins